Linked Life Data

19355878

Source:http://linkedlifedata.com/resource/pubmed/id/19355878

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19355878rdf:typepubmed:Citationlld:pubmed
pubmed-article:19355878lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0874159lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0682323lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0520484lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0525635lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0442120lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0205373lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C0066117lld:lifeskim
pubmed-article:19355878lifeskim:mentionsumls-concept:C1176299lld:lifeskim
pubmed-article:19355878pubmed:issue10lld:pubmed
pubmed-article:19355878pubmed:dateCreated2009-4-9lld:pubmed
pubmed-article:19355878pubmed:abstractTextAn intraperitoneal (IP) monotherapy in nu/nu mice with subcutaneous xenografts of a human prostate epithelial cancer cell line:DU145 was undertaken with an aldehyde dehydrogenase 3 inhibitor MATE, that is a potent apoptogen on (DU145) in culture but not on their human prostate epithelial normal counterparts [13] . Tumour growth was slowed down but treatment had to be done 5days/week. To try to potentiate the action of MATE in vivo, a bitherapy was undertaken based on the synergetic apoptotic effect that had been observed previously in culture on DU145 treated with a methional mimic METLICO and DIMATE, an inhibitor of ALDH1 and ALDH3 [19]. The bitherapy with METLICO/MATE administered IP was as effective as the monotherapy with MATE alone by IP, but at a 2-fold lower dose of MATE and at a dose of METLICO that had no growth-inhibitory effect as a monotherapy . Hence there was definite synergism with bitherapy. To try to increase the efficacy of bitherapy, it was administered by the intra-tumoral (IT) route using the recently developed 20-bars-pressurized microinjection system from CERMA [16, 17]. IT administration of the bitherapy was indeed more effective than that by IP as regards tumour volumes are concerned. Histopathological analysis of IT-treated tumours confirmed that there were many necrotized zones but intact cells were still present. Approaches for treating a wider zone of tumour tissue by IT-bitherapy are discussed.lld:pubmed
pubmed-article:19355878pubmed:languageenglld:pubmed
pubmed-article:19355878pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19355878pubmed:citationSubsetIMlld:pubmed
pubmed-article:19355878pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19355878pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19355878pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19355878pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19355878pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19355878pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19355878pubmed:statusMEDLINElld:pubmed
pubmed-article:19355878pubmed:issn0929-8673lld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:ReichertUUlld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:QuashGGlld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:HiltbrandEElld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:GoréJJlld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:MehierHHlld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:MorelDDlld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:ChantepieJJlld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:FournetGGlld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:GilibertoJ-PJ...lld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:ParetM-JMJlld:pubmed
pubmed-article:19355878pubmed:authorpubmed-author:RochedixM-EMElld:pubmed
pubmed-article:19355878pubmed:issnTypePrintlld:pubmed
pubmed-article:19355878pubmed:volume16lld:pubmed
pubmed-article:19355878pubmed:ownerNLMlld:pubmed
pubmed-article:19355878pubmed:authorsCompleteYlld:pubmed
pubmed-article:19355878pubmed:pagination1184-91lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:meshHeadingpubmed-meshheading:19355878...lld:pubmed
pubmed-article:19355878pubmed:year2009lld:pubmed
pubmed-article:19355878pubmed:articleTitleSynergetic bitherapy in mice with xenografts of human prostate cancer using a methional mimic (METLICO) and an aldehyde dehydrogenase 3 inhibitor (MATE): systemic intraperitoneal (IP) and targeted intra-tumoral (IT) administration.lld:pubmed
pubmed-article:19355878pubmed:affiliationCERMA, BioPark d'Archamps, F-74160, France.lld:pubmed
pubmed-article:19355878pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19355878pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed